Avidity-mediated discrimination between moderate and low HER3-expressing cells in combination with monovalent binding to the trigger molecule CD3 potentially lowers the risk of on-target off-tumor adverse effects which might lead to a preferable therapeutic window. This evidence concerns the gene ERBB3 and neoplasm.